https://www.selleckchem.com/pr....oducts/ZM-447439.htm
ing a period of 5.5 years. Moving forward, greater investigation of program usage, development, and efficacy is necessary. Level of evidence Level II therapeutic. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Background The use of tranexamic acid (TXA) has become increasingly prevalent for hemorrhage prevention in military trauma patients due to its known survival benefits. There is concern of increased venous thromboembolism (VTE) subsequen
Like
Comment
Share
